Table 4.
Echocardiographic variables at baseline and during follow‐up
| All (n = 50) | Baseline | 3 months | 6 months | 12 months |
|---|---|---|---|---|
| RA area, cm2 | 22.6 ± 7.3 | 22.7 ± 7.2 | 21.7 ± 7.5 | 20.9 ± 7.8* |
| RVEDD, mm | 44.3 ± 8.6 | 43.9 ± 8.3 | 42.3 ± 7.8* | 42.7 ± 8.9 |
| PASP, mmHg | 83.8 ± 21.5 | 69.7 ± 20.5* | 61.3 ± 17.6* | 59.8 ± 20.2* |
| TAPSE, mm | 19.1 ± 5.3 | 20.6 ± 5.4* | 20.5 ± 5.0 | 21.3 ± 4.3* |
| TAPSE/PASP, mm/mmHg | 0.26 ± 0.11 | 0.34 ± 0.15* | 0.37 ± 0.16* | 0.42 ± 0.23* |
| LVEDD, mm | 40.1 ± 5.7 | 42.5 ± 5.5* | 42.4 ± 5.7* | 42.6 ± 6.2* |
| LVEF, % | 62.3 ± 11.4 | 62.0 ± 11.1 | 61.7 ± 11.0 | 61.3 ± 10.8 |
| Classical PAH (n = 37) | ||||
| RA area, cm2 | 22.2 ± 7.8 | 22.7 ± 8.1 | 21.6 ± 8.3 | 20.4 ± 8.6* |
| RVEDD, mm | 45.1 ± 8.5 | 44.1 ± 8.2 | 42.4 ± 7.4* | 42.9 ± 8.9 |
| PASP, mmHg | 84.9 ± 22.7 | 71.1 ± 20.9* | 61.9 ± 16.6* | 62.8 ± 20.2* |
| TAPSE, mm | 19.7 ± 4.8 | 20.6 ± 5.3* | 20.3 ± 5.1 | 21.2 ± 4.3 |
| TAPSE/PASP, mm/mmHg | 0.25 ± 0.12 | 0.33 ± 0.16* | 0.36 ± 0.16* | 0.38 ± 0.16* |
| LVEDD, mm | 39.8 ± 5.9 | 41.8 ± 5.7 * | 41.9 ± 5.7* | 41.8 ± 6.4 |
| LVEF, % | 62.7 ± 11.5 | 62.6 ± 11.5 | 62.1 ± 11.4 | 61.4 ± 11.1 |
| PAH with co‐morbidities (n = 13) | ||||
| RA area, cm2 | 23.7 ± 5.6 | 22.8 ± 4.0 | 22.0 ± 4.2 | 22.1 ± 4.1 |
| RVEDD, mm | 42.4 ± 8.7 | 43.5 ± 8.5 | 41.9 ± 8.8 | 42.1 ± 9.0 |
| PASP, mmHg | 80.8 ± 17.2 | 65.3 ± 18.8* | 59.7 ± 20.2* | 51.0 ± 17.2* |
| TAPSE, mm | 17.7 ± 6.2 | 20.3 ± 5.6 | 21.3 ± 4.4 | 21.7 ± 4.2* |
| TAPSE/PASP, mm/mmHg | 0.24 ± 0.11 | 0.35 ± 0.12* | 0.40 ± 0.16* | 0.55 ± 0.35* |
| LVEDD, mm | 41.0 ± 5.3 | 44.2 ± 4.5* | 43.6 ± 5.4 | 45.0 ± 5.0* |
| LVEF, % | 61.3 ± 11.2 | 60.4 ± 9.7 | 61.0 ± 9.7 | 61.1 ± 10.0 |
LVEDD, left ventricular end‐diastolic diameter; LVEF, left ventricular ejection fraction; PAH, pulmonary arterial hypertension; PASP, pulmonary artery systolic pressure; RA, right atrium, RVEDD, right ventricular end‐diastolic diameter; TAPSE, tricuspid annular plane systolic excursion.
*
P < 0.05.